公开(公告)号：US20210186897A1

公开(公告)日：2021-06-24

申请号：US17125741

申请日：2020-12-17

Applicant: CURASEN THERAPEUTICS, INC.

Inventor： Anthony P. Ford ,  Gabriel Vargas

IPC: A61K31/136 ,  A61K31/138 ,  A61P25/28 ,  A61P25/16 ,  A61P25/24

Abstract: In various aspects and embodiments provided are compositions and methods for identifying patients in need of improving cognition and/or treating a neurodegenerative disease in a patient and treating such patient. More specifically, the disclosure in some embodiments includes administration of a β-AR agonist and a peripherally acting β-blocker (PABRA) to a patient in need thereof.

公开(公告)号：US10947196B2

公开(公告)日：2021-03-16

申请号：US16831370

申请日：2020-03-26

Applicant: CURASEN THERAPEUTICS, INC.

Inventor： Anthony P. Ford ,  Wei Chen ,  David Scott Carter ,  Jiaxin Yu

IPC: C07D213/30 ,  C07D209/42 ,  A61K9/00 ,  A61P25/30 ,  A61P25/28 ,  A61P25/16

Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.

公开(公告)号：US20230263749A1

公开(公告)日：2023-08-24

申请号：US18023693

申请日：2021-08-31

Applicant: CuraSen Therapeutics, Inc.

Inventor： Anthony P. Ford ,  Gabriel Vargas ,  Wei Chen ,  Renee S. Martin

IPC: A61K31/138 ,  A61K31/165 ,  A61K31/18 ,  A61K31/166 ,  A61K31/137 ,  A61P25/28 ,  A61B6/00 ,  A61B6/03

CPC classification number: A61K31/138 ,  A61K31/165 ,  A61K31/18 ,  A61K31/166 ,  A61K31/137 ,  A61P25/28 ,  A61B6/501 ,  A61B6/037 ,  A61B5/055

Abstract: In various aspects and embodiments provided are compositions and methods for identifying patients in need of improving cognition and/or treating a neurodegenerative disease in a patient and treating such patient. More specifically, the disclosure in some embodiments includes administration of a β-AR agonist (such as a β-agent) and a peripherally acting β-blocker (PABRA) to a patient in need thereof.

公开(公告)号：US11040944B2

公开(公告)日：2021-06-22

申请号：US16831285

申请日：2020-03-26

Applicant: CURASEN THERAPEUTICS, INC.

Inventor： Anthony P. Ford ,  Wei Chen ,  David Scott Carter ,  Jiaxin Yu

IPC: C07D209/42 ,  A61K9/00 ,  A61P25/30 ,  A61P25/28 ,  A61P25/16

Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.

公开(公告)号：US20240352002A1

公开(公告)日：2024-10-24

申请号：US18035262

申请日：2021-11-18

Applicant: Curasen Therapeutics, Inc.

Inventor： Jiaxin Yu ,  David Scott Carter ,  Anthony P. Ford ,  Wei Chen

IPC: C07D403/06 ,  A61K31/397 ,  A61K31/4035 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  C07D205/04 ,  C07D207/08 ,  C07D213/30 ,  C07D213/73 ,  C07D213/84 ,  C07D239/42 ,  C07D401/06 ,  C07D405/06 ,  C07D413/06 ,  C07D417/06

CPC classification number: C07D403/06 ,  A61K31/397 ,  A61K31/4035 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  C07D205/04 ,  C07D207/08 ,  C07D213/30 ,  C07D213/73 ,  C07D213/84 ,  C07D239/42 ,  C07D401/06 ,  C07D405/06 ,  C07D413/06 ,  C07D417/06

Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor. Disclosed herein is a compound according to Formula (I) or an optically pure stereoisomer, pharmaceutically acceptable salt, solvate, or prodrug thereof. Further disclosed herein is a compound according to Formula (II) or an optically pure stereoisomer, pharmaceutically acceptable salt, solvate, or prodrug thereof.

公开(公告)号：US20220401415A1

公开(公告)日：2022-12-22

申请号：US17770276

申请日：2020-10-23

Applicant: Curasen Therapeutics, Inc.

Inventor： Anthony P. Ford

IPC: A61K31/4164 ,  A61P9/02

Abstract: In various aspects and embodiments provided are compositions and methods for a disease or disorder in a patient such as a disease or disorder that affects the brain in a patient and treating such patient.

公开(公告)号：US20210121445A1

公开(公告)日：2021-04-29

申请号：US17100758

申请日：2020-11-20

Applicant: CuraSen Therapeutics, Inc.

Inventor： Anthony P. Ford

IPC: A61K31/4164 ,  A61P9/02

Abstract: In various aspects and embodiments provided are compositions and methods for a disease or disorder in a patient such as a disease or disorder that affects the brain in a patient and treating such patient.

公开(公告)号：US20200308115A1

公开(公告)日：2020-10-01

申请号：US16831370

申请日：2020-03-26

Applicant: CURASEN THERAPEUTICS, INC.

Inventor： Anthony P. Ford ,  Wei Chen ,  David Scott Carter ,  Jiaxin Yu

IPC: C07D209/42 ,  A61K9/00 ,  A61P25/28 ,  A61P25/16 ,  A61P25/30

Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.

公开(公告)号：US20200308114A1

公开(公告)日：2020-10-01

申请号：US16831285

申请日：2020-03-26

Applicant: CURASEN THERAPEUTICS, INC.

Inventor： Anthony P. Ford ,  Wei Chen ,  David Scott Carter ,  Jiaxin Yu

IPC: C07D209/42 ,  A61K9/00 ,  A61P25/28 ,  A61P25/16 ,  A61P25/30

Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.

公开(公告)号：US20240270701A1

公开(公告)日：2024-08-15

申请号：US18694362

申请日：2022-09-22

Applicant: Curasen Therapeutics, Inc.

Inventor： Jiaxin Yu ,  Anthony P. Ford ,  Wei Chen

IPC: C07D241/42 ,  A61K31/4045 ,  A61K31/416 ,  A61K31/417 ,  A61K31/426 ,  A61K31/437 ,  A61K31/44 ,  A61K31/47 ,  A61K31/498 ,  A61K31/517 ,  C07D209/34 ,  C07D213/38 ,  C07D213/61 ,  C07D213/73 ,  C07D215/14 ,  C07D215/233 ,  C07D231/56 ,  C07D235/08 ,  C07D235/26 ,  C07D237/20 ,  C07D239/42 ,  C07D239/74 ,  C07D277/40 ,  C07D277/68 ,  C07D471/04

CPC classification number: C07D241/42 ,  A61K31/4045 ,  A61K31/416 ,  A61K31/417 ,  A61K31/426 ,  A61K31/437 ,  A61K31/44 ,  A61K31/47 ,  A61K31/498 ,  A61K31/517 ,  C07D209/34 ,  C07D213/38 ,  C07D213/61 ,  C07D213/73 ,  C07D215/14 ,  C07D215/233 ,  C07D231/56 ,  C07D235/08 ,  C07D235/26 ,  C07D237/20 ,  C07D239/42 ,  C07D239/74 ,  C07D277/40 ,  C07D277/68 ,  C07D471/04

Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor. An advantage of the compounds provided herein is that a broad range of pharmacological activities is possible, consistent with modulation of beta-adrenergic receptors. In addition, the disclosure provides methods of using the compounds described herein for the treatment of diseases associated with an adrenergic receptor, including but not limited to neurodegenerative diseases and disorders.